Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Groups 1 and 2 Inclusion Criteria:~* HIV-uninfected males or females age 18-50 years old~* Willing to maintain low risk behavior for HIV infection~Groups 1 and 2 Exclusion Criteria:~• Confirmed HIV-infection, pregnancy or lactation, significant acute or chronic disease and clinically significant laboratory abnormalities~Group 3 Inclusion Criteria:~* HIV-infected males or females age 18-65 years old~* Not on antiretroviral therapy with HIV-1 RNA plasma level between 1,000 and 100,000 copies/ml, CD4 cell count ≥ 300 cells/uL~Group 3 Exclusion Criteria:~• Significant acute or chronic medical condition other than HIV infection, and clinically significant laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group 1A HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 low dose
- Group 1B HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 mid dose
- Group 1C HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 high dose
- Group 2A HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 + PGT121 low dose
- Group 2B HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 + PGT121 mid dose
- Group 2C HIV-Uninfected (Type: EXPERIMENTAL): PGDM1400 + PGT121 high dose
- Group 3A HIV-infected off ART (Type: EXPERIMENTAL): PGDM1400 + PGT121 + VRC07-523LS at 20mg/kg; HIV+ without ART
- Group 3B HIV-infected off ART (Type: EXPERIMENTAL): PGDM1400 + PGT121 at high dose; HIV + without ART

Based on this trial design, predict the completion outcome and termination type (if applicable).